PAR-1 inhibitors: Difference between revisions
No edit summary |
No edit summary |
||
(2 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
Protease Activated Receptor ('''PAR''')-'''1''' '''inhibitors''' (also known as thrombin receptor antagonists) are a new class of antiplatelet agents that '''antagonize platelet activation mediated by thrombin''', the most potent platelet activator. | {{SI}} | ||
'''Editors-In-Chief:''' Sergio Leonardi, M.D., Duke Clinical Research Institute; [[C. Michael Gibson]], M.S., M.D. | |||
==Overview== | |||
Protease Activated Receptor ('''PAR''')-'''1''' '''inhibitors''' (also known as thrombin receptor antagonists, TRAs) are a new class of antiplatelet agents that '''antagonize platelet activation mediated by thrombin''', the most potent platelet activator. | |||
The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. | The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. | ||
The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation. | The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation. | ||
The 2 agents in most advanced clinical development are | The 2 agents in most advanced clinical development are '''[[vorapaxar]]''' (previously known as SCH530348) and '''[[atopaxar]]''' (previously known as E-5555). | ||
{{WH}} | |||
{{WS}} |
Latest revision as of 13:23, 26 October 2010
WikiDoc Resources for PAR-1 inhibitors |
Articles |
---|
Most recent articles on PAR-1 inhibitors Most cited articles on PAR-1 inhibitors |
Media |
Powerpoint slides on PAR-1 inhibitors |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on PAR-1 inhibitors at Clinical Trials.gov Trial results on PAR-1 inhibitors Clinical Trials on PAR-1 inhibitors at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on PAR-1 inhibitors NICE Guidance on PAR-1 inhibitors
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on PAR-1 inhibitors Discussion groups on PAR-1 inhibitors Patient Handouts on PAR-1 inhibitors Directions to Hospitals Treating PAR-1 inhibitors Risk calculators and risk factors for PAR-1 inhibitors
|
Healthcare Provider Resources |
Causes & Risk Factors for PAR-1 inhibitors |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editors-In-Chief: Sergio Leonardi, M.D., Duke Clinical Research Institute; C. Michael Gibson, M.S., M.D.
Overview
Protease Activated Receptor (PAR)-1 inhibitors (also known as thrombin receptor antagonists, TRAs) are a new class of antiplatelet agents that antagonize platelet activation mediated by thrombin, the most potent platelet activator.
The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation. The 2 agents in most advanced clinical development are vorapaxar (previously known as SCH530348) and atopaxar (previously known as E-5555).